Sales · healthcareJul 202610 min read338 words

Discovery calls: a case study playbook for healthcare and life sciences

The anatomy of a discovery calls engagement that worked — what we tried, what we killed, and what we would repeat. Written for commercial leaders at healthtech, medtech, and life-sciences companies.

This edition is written for commercial leaders at healthtech, medtech, and life-sciences companies. In healthcare and life sciences, healthcare buyers move under regulatory constraint and reward domain-specific messaging, so the way you install discovery calls has to reflect that reality from day one.

Names removed, numbers preserved. This is a real discovery calls engagement, reproduced as a playbook. Client had product-market fit, a rev team of eleven, and a stalled pipeline.

Week one: diagnosis. The stated problem was "not enough leads". The actual problem was reading a script instead of running a diagnosis, which had been masked by inbound velocity that peaked two quarters earlier.

Weeks two to three: rebuild the target list from scratch and re-cut the trigger. Discovery calls works when everything after discovery is downstream of what you learned in it; the client had drifted away from that first principle.

The binding constraint we see in healthcare and life sciences is almost always regulated-sale cycle length, not intent. Discovery calls is only useful in this vertical when it is pointed at that constraint — not at a generic growth number borrowed from another category.

Weeks four to six: live at 20% of previous volume, quality bar raised. Discovery-to-opportunity conversion moved every week, though absolute numbers stayed modest.

Weeks seven to twelve: ramp. By week ten the number was ahead of the pre-stall baseline. By week twelve it was 40% ahead. Cost per outcome was roughly halved.

What we would repeat: the diagnosis step, the quality bar, and the weekly review. What we would kill sooner: two tools we bought in month one that added noise instead of leverage.

The client's own summary at the end of quarter one: "we thought we needed more of everything; we actually needed less of the wrong things." That is usually the lesson.

Concretely for healthcare and life sciences: the healthcare teams that install this get past procurement instead of dying in it. That is the reason it is worth installing discovery calls properly rather than half-heartedly across three vendors.

discovery callssales discoveryMEDDICdiscovery calls case studydiscovery calls playbookdiscovery calls for healthcare and life scienceshealthcare discovery callshealthcare and life sciences growth

Frequently asked questions

Sales · healthcare — answered

Does discovery calls work for healthcare and life sciences?
Yes — provided it is aimed at regulated-sale cycle length, not intent rather than a generic growth number. The healthcare teams that install this get past procurement instead of dying in it.
How long until the case study company saw results?
The metric moved in week four; the absolute number caught up around week ten.
What did the client stop doing?
Running old tools on autopilot and confusing volume with progress.
What did the client keep doing?
The Monday plan, the Friday review, and the weekly discovery-to-opportunity conversion readout.
Is this case study repeatable?
The process is repeatable; the numbers depend on category, team, and starting point.
What is the healthcare specific pitfall with discovery calls?
Running the generic playbook without adapting to healthcare buyers move under regulatory constraint and reward domain-specific messaging. The install has to be vertical-first.

Growth Broker editorial

Filed under sales · healthcare

Up next

Discovery calls templates and swipe files for healthcare and life sciences

Read piece

Ready to broker your growth?

Book a Growth Call